Seed Biotech pitch decks mapped to value-inflecting milestones.
Seed-stage biotech investors fund a lead program toward candidate nomination or IND-enabling work. The deck must present the data package with rigor, map the development plan to milestones that step up value, and show a team that can execute translational science.
At a glance
- Typical deck length
- 12–15 slides
- Who you're pitching
- Seed funds, multi-stage firms' seed practices, angels and syndicates leading or following early institutional rounds.
- Lead with
- Lead-program efficacy data · Development timeline · Milestone-based budget




What Seed Biotech investors need to believe.
A Biotech round at Seed turns on a handful of beliefs. Your deck should build each one before a partner has to ask.
The lead program is differentiated
Data suggests a meaningful advantage over standard of care or competing approaches.
The path to the clinic is clear
Candidate selection, IND-enabling studies and timelines are mapped realistically.
Milestones step up value
Each funded milestone is a recognizable de-risking event for the next investor.
The team can translate
Scientific founders are paired with drug-development or regulatory experience.
What to lead with at Seed.
At this stage, these are the numbers and evidence that carry the room. Each one should tie out to your model and data room.
Lead-program efficacy data
Show the key in vivo results against relevant comparators with clear statistics.
Development timeline
Map candidate nomination, IND-enabling studies and IND filing on one roadmap.
Milestone-based budget
Show cost per milestone and the runway to the next value inflection.
Competitive landscape
Compare against programs in development by mechanism and stage.
IP and exclusivity
Summarize patent coverage and expected exclusivity period.
How to structure a Seed Biotech deck.
A 12–15 slides structure tuned for this round. Tap any slide for the full guide.
-
Title Slide
At seed, the title slide can lean on an early proof point — a pilot customer type or a launch milestone — alongside a sharp one-liner.
-
Problem Slide
At seed, back the problem with early customer evidence — pilot conversations, waitlist demand or quotes from users who already rely on you.
-
Solution Slide
At seed, show the solution working in the real world — early users, a live product and the first evidence that it delivers the promised outcome.
-
Why Now Slide
At seed, pair the timing argument with early signs the window is opening — customers adopting faster than expected or new buyers appearing.
-
Market Size Slide
At seed, tighten the bottom-up model with real pricing signals from early customers and a sharper definition of the initial segment.
-
Product Slide
Present the pipeline as a value-inflection map — each program against its next milestone and data readout.
Biotech-specific -
Traction Slide
At seed, show early revenue or usage with a clear growth trend, plus retention signals that suggest product-market fit is emerging.
-
Business Model Slide
At seed, back the model with real pricing — early contracts, conversion from pilots or willingness-to-pay evidence from customers.
-
Go-to-Market Slide
At seed, show the first channel working — early conversion data, founder-led sales results or organic pull from a specific segment.
-
Competition Slide
Use a landscape grid by mechanism and development stage rather than a generic 2×2.
Biotech-specific -
Team Slide
Pair scientific founders with drug-development, CMC or regulatory advisors and their relevant track records.
Biotech-specific -
Financials Slide
At seed, show a basic projection driven by clear assumptions, with early revenue as the anchor and runway to Series A milestones.
-
The Ask & Use of Funds Slide
At seed, connect the raise to the metrics investors will expect at Series A, with use of funds weighted toward product and early go-to-market.
What Biotech investors will push on at Seed.
Why will this beat the competitors already in the clinic?
How the deck answers it: Show differentiation on efficacy, safety, dosing or patient selection with head-to-head or benchmark data.
Is the budget realistic for IND-enabling work?
How the deck answers it: Break out CRO and CMC costs with vendor quotes or precedent ranges.
What's the platform beyond one asset?
How the deck answers it: Show how the approach generates follow-on programs without diluting focus on the lead.
Trusted by founders. Backed by results.
They were able to give us insight into a comprehensive and emerging landscape. They provided further resources with case studies and data to make our arguments more compelling; while being timely and communicative. They're an asset to any team moving forward.
[They] were educated in the biopharma space and was able to give us insight into the landscape. They provided further resources/data to make our arguments more compelling. He was timely and communicative. An asset to any team moving forward.
(For our acquisition of Modular Water), they really built the case with deep research. Highly professional. They took the time to work through a number of iterations of the project and maintained outstanding communication. Highly recommend.
Common questions. Clear answers.
What milestones should a seed biotech round fund?
How detailed should the science be in a seed biotech deck?
What does a custom engagement cost?
How fast can you turn it around?
Keep exploring.
Raising your Seed round? Get the deck right first.
Drop your details and we'll send a free deck audit — then jump on a 15-minute intro call to walk through exactly what to fix before you pitch.
- We reply within 24 hours
- Complete founder confidentiality
Got it — your audit is on the way.
We'll review your details and reply within 24 hours. Want to fast-track it? Grab a 15-minute intro call now.
Book your intro call